RT Journal Article
SR Electronic
T1 A Phase I Study of Concurrent Chemoradiotherapy and Cetuximab for Locally Advanced Esophageal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4019
OP 4023
VO 32
IS 9
A1 CECILIE HOLLÄNDER
A1 LENE BAEKSGAARD
A1 MORTEN SORENSEN
A1 PER ALBERTSSON
A1 LARS DAMSTRUP
A1 ULRIK LASSEN
YR 2012
UL http://ar.iiarjournals.org/content/32/9/4019.abstract
AB Aim: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer. Patients and Methods: Escalating doses of oxaliplatin every second week and daily tegafur/uracil were given concurrently with radiotherapy, 59.4 Gy in 33 fractions. Cetuximab was given on day 15 (400 mg/m2) and weekly (250 mg/m2) during radiotherapy. Fixed doses of oxaliplatin (130 mg/m2) and tegafur/uracil (300 mg/m2) were administered before, and after radiotherapy. Results: Eleven patients were included in the study; two were excluded due to allergic reactions to cetuximab. In DL2 (tegafur/uracil 300 mg/m2, oxaliplatin 30 mg/m2) two grade 3/4 fistula and one grade 3 neuropathy were observed. Six patients were enrolled in DL1 (tegafur/uracil 150 mg/m2/, oxaliplatin 30 mg/m2) with no DLTs. Four out of 9 patients had complete response. Conclusion: Concomitant chemoradiotherapy and cetuximab had significant activity. DL1 was established as the MTD.